José Manuel Fernández-Real1, Donald McClain2, Melania Manco3. 1. University Hospital of Girona "DrJosepTrueta," Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigació Biomèdica de Girona (IdIBGi), Girona, Spain CIBER Fisiopatología de la Obesidad y Nutrición, Girona, Spain jmfreal@idibgi.org. 2. Departments of Biochemistry and Internal Medicine, University of Utah, Salt Lake City, UT Veterans Administration Research Service, Salt Lake City VAHCS, Salt Lake City, UT. 3. Bambino Gesù Children's Hospital and Research Institute, Research Unit for Multifactorial Disease, Rome, Italy.
Abstract
OBJECTIVE: The bidirectional relationship between iron metabolism and glucose homeostasis is increasingly recognized. Several pathways of iron metabolism are modified according to systemic glucose levels, whereas insulin action and secretion are influenced by changes in relative iron excess. We aimed to update the possible influence of iron on insulin action and secretion and vice versa. RESEARCH DESIGN AND METHODS: The mechanisms that link iron metabolism and glucose homeostasis in the main insulin-sensitive tissues and insulin-producing β-cells were revised according to their possible influence on the development of type 2 diabetes (T2D). RESULTS: The mechanisms leading to dysmetabolic hyperferritinemia and hepatic overload syndrome were diverse, including diet-induced alterations in iron absorption, modulation of gluconeogenesis, heme-mediated disruption of circadian glucose rhythm, impaired hepcidin secretion and action, and reduced copper availability. Glucose metabolism in adipose tissue seems to be affected by both iron deficiency and excess through interaction with adipocyte differentiation, tissue hyperplasia and hypertrophy, release of adipokines, lipid synthesis, and lipolysis. Reduced heme synthesis and dysregulated iron uptake or export could also be contributing factors affecting glucose metabolism in the senescent muscle, whereas exercise is known to affect iron and glucose status. Finally, iron also seems to modulate β-cells and insulin secretion, although this has been scarcely studied. CONCLUSIONS: Iron is increasingly recognized to influence glucose metabolism at multiple levels. Body iron stores should be considered as a potential target for therapy in subjects with T2D or those at risk for developing T2D. Further research is warranted.
OBJECTIVE: The bidirectional relationship between iron metabolism and glucose homeostasis is increasingly recognized. Several pathways of iron metabolism are modified according to systemic glucose levels, whereas insulin action and secretion are influenced by changes in relative iron excess. We aimed to update the possible influence of iron on insulin action and secretion and vice versa. RESEARCH DESIGN AND METHODS: The mechanisms that link iron metabolism and glucose homeostasis in the main insulin-sensitive tissues and insulin-producing β-cells were revised according to their possible influence on the development of type 2 diabetes (T2D). RESULTS: The mechanisms leading to dysmetabolic hyperferritinemia and hepatic overload syndrome were diverse, including diet-induced alterations in iron absorption, modulation of gluconeogenesis, heme-mediated disruption of circadian glucose rhythm, impaired hepcidin secretion and action, and reduced copper availability. Glucose metabolism in adipose tissue seems to be affected by both iron deficiency and excess through interaction with adipocyte differentiation, tissue hyperplasia and hypertrophy, release of adipokines, lipid synthesis, and lipolysis. Reduced heme synthesis and dysregulated iron uptake or export could also be contributing factors affecting glucose metabolism in the senescent muscle, whereas exercise is known to affect iron and glucose status. Finally, iron also seems to modulate β-cells and insulin secretion, although this has been scarcely studied. CONCLUSIONS:Iron is increasingly recognized to influence glucose metabolism at multiple levels. Body iron stores should be considered as a potential target for therapy in subjects with T2D or those at risk for developing T2D. Further research is warranted.
Authors: Donald A McClain; Neeraj K Sharma; Shalini Jain; Alexandria Harrison; Lipika N Salaye; Mary E Comeau; Carl D Langefeld; Felipe R Lorenzo; Swapan K Das Journal: J Clin Endocrinol Metab Date: 2018-11-01 Impact factor: 5.958
Authors: Laura M Raffield; Tin Louie; Tamar Sofer; Deepti Jain; Eli Ipp; Kent D Taylor; George J Papanicolaou; Larissa Avilés-Santa; Leslie A Lange; Cathy C Laurie; Matthew P Conomos; Timothy A Thornton; Yii-Der Ida Chen; Qibin Qi; Scott Cotler; Bharat Thyagarajan; Neil Schneiderman; Jerome I Rotter; Alex P Reiner; Henry J Lin Journal: Hum Mol Genet Date: 2017-05-15 Impact factor: 6.150
Authors: Driton Vela; Jovica Leshoski; Elizabeta S Gjorgievska; Nikola Hadzi-Petrushev; Muharrem Jakupaj; Ramadan B Sopi; Mitko Mladenov Journal: Oman Med J Date: 2017-05
Authors: Benjamin J Ryan; Douglas W Van Pelt; Lisa M Guth; Alison C Ludzki; Rachel A Gioscia-Ryan; Chiwoon Ahn; Katherine L Foug; Jeffrey F Horowitz Journal: Exp Physiol Date: 2018-10-08 Impact factor: 2.969
Authors: Matthew A Stroh; Michelle K Winter; Russell H Swerdlow; Kenneth E McCarson; Hao Zhu Journal: Metab Brain Dis Date: 2016-05-18 Impact factor: 3.584
Authors: M Angeles Zulet; Itziar Abete; Cristina Galarregui; Irene Cantero; Bertha Araceli Marin-Alejandre; J Ignacio Monreal; Mariana Elorz; Alberto Benito-Boillos; José Ignacio Herrero; Víctor de la O; Miguel Ruiz-Canela; Helen Hermana M Hermsdorff; Josefina Bressan; Josep A Tur; J Alfredo Martínez Journal: Eur J Nutr Date: 2020-08-28 Impact factor: 5.614